Engineered t cells take on lymphoma in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PROCUREMENT Inclusion Criteria: 1. Diagnosis of relapsed/refractory HL or NHL. 2. CD30 positive tumor as assayed in a CLIA certified pathology laboratory (result can be pending at this time) 3. Hgb ≥ 7.0 (may be a transfused value) 4. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent. 5. Karnofsky or Lansky score of \> 60% TREATMENT Inclusion Criteria: 1. Diagnosis of relapsed/refractory HL or NHL. 2. CD30-positive tumor as assayed in a CLIA certified pathology laboratory. 3. Age 16 to 75 for the first three patients on a dose level; thereafter, if no DLT, patients aged 12 to 75 can be treated on that dose level. 4. Bilirubin 1.5 times or less than the upper limit of normal. 5. AST 3 times or less than the upper limit of normal. 6. Estimated GFR \> 70 mL/min. 7. Pulse oximetry of \> 90% on room air 8. EKG shows no significant arrhythmias 9. Karnofsky or Lansky score of \> 60%. 10. Available autologous T cells with greater than or equal to 15% expression of CD30CAR determined by flow-cytometry. 11. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy. 12. Adequate pulmonary function with FEV1, FVC and DLCO (or DLCO/VA, as clinically appropriate) greater than or equal to 50% of expected corrected for hemoglobin. 13. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom. 14. Informed consent explained to, understood by and signed by patient or guardian. PROCUREMENT Exclusion Criteria: 1. Active infection with HIV or HTLV (can be pending at this time). 2. Active bacterial, fungal or viral infection. TREATMENT Exclusion Criteria: 1. Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks. 2. Received anti-CD30 antibody-based therapy within the previous 4 weeks. 3. Subjects with rapidly progressive disease, defined as kinetic failure to previous chemotherapy. 4. Bulky disease (defined as a 10 cm or greater mass or mediastinal disease with a transverse diameter exceeding 33% of the transthoracic diameter). 5. History of hypersensitivity reactions to murine protein-containing products. 6. Pregnant or lactating. 7. Tumor in a location where enlargement could cause airway obstruction. 8. Current use of systemic corticosteroids at a dose equivalent to 0.5 mg/kg/day of prednisone or higher. 9. Active hemorrhagic cystitis. 10. Active bacterial, viral or fungal infection. 11. Symptomatic cardiac disease (NYHA Class III or IV disease).